Protein-Losing Enteropathy and the Fontan Operation

被引:55
作者
Johnson, Jonathan N. [1 ]
Driscoll, David J. [1 ]
O'Leary, Patrick W. [1 ,2 ]
机构
[1] Mayo Clin, Coll Med, Dept Pediat, Div Pediat Cardiol, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA
关键词
protein-losing enteropathies; Fontan procedure; IN-VITRO MODEL; CARDIAC TRANSPLANTATION; VASCULAR-RESISTANCE; ORAL BUDESONIDE; CIRCULATION; FENESTRATION; RESOLUTION; THERAPY; HEPARIN; DESIGN;
D O I
10.1177/0884533612444532
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Protein-losing enteropathy (PLE) is a complex disorder characterized by enteric protein loss and often is associated with cardiovascular abnormalities, particularly those with elevated central venous pressure. The Fontan operation is a surgical procedure used to palliate patients with a functional single ventricle. Although the Fontan operation eliminates cyanosis and decreases the workload of the functionally single ventricle, it also elevates central venous pressure. This can result in hepatic and enteric congestion as well as PLE. Despite the universal elevation in central venous pressure, only a fraction of patients who have had a Fontan operation develop PLE. However, PLE is associated with significant morbidity and mortality. Presenting signs and symptoms of PLE include abdominal bloating, diarrhea, edema, pleural effusions, ascites, and failure to thrive. In this review, the authors discuss the diagnosis and prevalence of PLE after the Fontan operation and review currently available therapeutic strategies. (Nutr Clin Pract. 2012;27:375-384)
引用
收藏
页码:375 / 384
页数:10
相关论文
共 46 条
[1]  
Amaral Fernando Tadeu Vasconcelos, 2006, Arq. Bras. Cardiol., V87, pe156, DOI 10.1590/S0066-782X2006001700036
[2]   Fontan and the pulmonary circulation: a potential role for new pulmonary hypertension therapies [J].
Beghetti, Maurice .
HEART, 2010, 96 (12) :911-916
[3]   Outcome of listing for cardiac transplantation for failed Fontan - A multi-institutional study [J].
Bernstein, D. ;
Naftel, D. ;
Chin, C. ;
Addonizio, L. J. ;
Gamberg, P. ;
Blume, E. D. ;
Hsu, D. ;
Canter, C. E. ;
Kirklin, J. K. ;
Morrow, W. R. .
CIRCULATION, 2006, 114 (04) :273-280
[4]   Resolution of protein-losing enteropathy with low-molecular weight heparin in an adult patient with Fontan palliation [J].
Bhagirath, Kapil M. ;
Tam, James W. .
ANNALS OF THORACIC SURGERY, 2007, 84 (06) :2110-2112
[5]   Heparan sulfate plays a central role in a dynamic in vitro model of protein-losing enteropathy [J].
Bode, L ;
Murch, S ;
Freeze, HH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (12) :7809-7815
[6]   Heparan sulfate depletion amplifies TNF-α-induced protein leakage in an in vitro model of protein-losing enteropathy [J].
Bode, L ;
Eklund, EA ;
Murch, S ;
Freeze, HH .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2005, 288 (05) :G1015-G1023
[7]  
Cohen MI, 2000, CARDIOL YOUNG, V10, P447
[8]   Atrial pacing: An alternative treatment for protein-losing enteropathy after the Fontan operation [J].
Cohen, MI ;
Rhodes, LA ;
Wernovsky, G ;
Gaynor, JW ;
Spray, TL ;
Rychik, J .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 121 (03) :582-583
[9]   PROTEIN-LOSING ENTEROPATHY AFTER FONTAN OPERATION FOR TRICUSPID ATRESIA (IMPERFORATE TRICUSPID-VALVE) [J].
CRUPI, G ;
LOCATELLI, G ;
TIRABOSCHI, R ;
VILLANI, M ;
DETOMMASI, M ;
PARENZAN, L .
THORACIC AND CARDIOVASCULAR SURGEON, 1980, 28 (05) :359-363
[10]  
DAVIDSON JD, 1961, LANCET, V1, P899